Dyslipidemia

Diabetes

Prediabetes

Dysglycemia

Gout

Hypertension

Non-alcoholic Fatty Liver Disease

Cardiovascular Disease

An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet

Fructose-containing Sugars

The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital

Meta-analyses of the Effect of Important Food Sources of Sugars on Cardiometabolic Risk Factors

Effect of Important Food Sources of Fructose-containing Sugars on Cardiometabolic Risk Factors: A Series of Systematic Reviews and Meta-analyses of Controlled Trials to Inform Dietary Guidelines, Public Health Policy, and Future Trial Design

glycated blood proteins, fasting blood glucose, fasting blood insulin

LDL-cholesterol, apol B, non-HDL-cholesterol, HDL-cholesterol, triglycerides

Intrahepatocellular lipid concentrations (IHCL), ALT

John Sievenpiper

Associate Professor

University of Toronto

Canadian Diabetes Association

The Physicians' Services Incorporated Foundation

Banting & Best Diabetes Centre

RUTF fortified with polyunsaturated fatty acids (PUFA) at a dose of 175 kcal/kg/d

Kwashiorkor

Marasmus

RUTF

RUTF-P

Amoxicillin

University of Malawi College of Medicine

Pilot Study of PUFA-optimized RUTF for Severe Acute Malnutrition

A Randomized, Double-blind Pilot Study of Polyunsaturated Fatty Acid-optimized Ready-to-use Therapeutic Food, Compared to Standard RUTF, in the Therapy of Severe Acute Malnutrition

Blood plasma docosahexaenoic acid (DHA) levels

Blood plasma eicosapentaenoic acid (EPA) levels

Proportion of children who recover from SAM

Washington University School of Medicine

University of Malawi

Cardiovascular Disease, Inflammation

High DHA

High EPA

Placebo

Institute of Nutrition and Functional Foods (INAF), Laval University

Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation (n3)

Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation in Men and Women With Metabolic Syndrome

Change between treatments based on post-treatment values, adjusting for treatment-specific baseline values

Change between treatments based on post-treatment values

Benoit Lamarche

Professor

Laval University

Canadian Institutes of Health Research (CIHR)

Chronic Kidney Disease

Hypertriglyceridemia

Children will be prescribed 1600-1800 mg EPA + DHA per m2 Body Surface Area, to a maximum of the upper limit of the age-appropriate range recommended by Health Canada.
Each n-3FA gel capsule (1000 mg) will contain 400 mg EPA and 200 mg DHA derived from the oil of wild anchovies and sardines. A smaller gel capsule (500 mg; 200 mg EPA + 100 mg DHA) will be available for children unable to swallow large solid medication and a flavored liquid formulation, containing a similar proportion of EPA + DHA (2200 mg fish oil concentrate from anchovies and sardines, 750 mg EPA, 375 mg DHA per ½ teaspoon), will be available for use in toddlers and older children unable to swallow gel capsules.

n-3 Fatty Acid supplement

The placebo, identical in opaque appearance and citrus-flavored taste, will contain a 50:50 blend of soybean and corn oil for both gel capsule (2 sizes) and liquid formulations.

The Hospital for Sick Children

Omega-3 Fatty Acid Supplementation in Children

Omega-3 Fatty Acid Supplementation to Treat Hypertriglyceridemia in Children With Chronic Kidney Disease

Sustainability of TG-lowering effects up to 4 weeks after stopping supplements

zea/antifungal

Meta-analyses of the Effect of Important Food Sources of Sugars on Cardiometabolic Risk Factors

Pilot Study of PUFA-optimized RUTF for Severe Acute Malnutrition

Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation (n3)

Omega-3 Fatty Acid Supplementation in Children

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht